Researchers from Emory University, the U.S. CDC and collaborators have identified a broad-spectrum antiviral agent able to combat highly pathogenic arenaviruses. The compound, a ribonucleoside analogue that acts through RdRp inhibition, exhibited a good pharmacokinetic profile, oral bioavailability and tissue distribution in guinea pigs, while protecting animals from lethal challenges with Lassa and Junín viruses, even at very low doses.

Clostridioides difficile is a gram-positive bacteria that causes disease in persons with dysbiosis of the gut microbiota and has been listed as an urgent threat due to the emergence of resistance.

In what represents the first patenting from Glasgow-based Microplate Dx Ltd., three of its co-founders describe a system for diagnosing microbial infections and performing rapid antimicrobial susceptibility testing, enabling quicker and more precise determination of effective antibiotics.

Researchers from presented preclinical data for AVX-70371, a novel therapeutic vaccine being developed for the treatment of chronic hepatitis B virus (HBV) infection.

Researchers from the University of Washington are developing new antibiotics targeting bacterial methionyl-tRNA synthetase (MetRS). This enzyme is responsible for charging tRNA(met) with methionine and integral to protein synthesis.

Researchers from Emory University, the U.S. CDC and collaborators have identified a broad-spectrum antiviral agent able to combat highly pathogenic arenaviruses. The compound, a ribonucleoside analogue that acts through RdRp inhibition, exhibited a good pharmacokinetic profile, oral bioavailability and tissue distribution in guinea pigs, while protecting animals from lethal challenges with Lassa and Junín viruses, even at very low doses.